博瑞医药: 关于开展2025年度远期外汇交易业务的公告

Core Viewpoint - 博瑞生物医药（苏州）股份有限公司 plans to conduct forward foreign exchange trading to mitigate risks associated with foreign exchange rate and interest rate fluctuations, with a maximum transaction amount not exceeding the equivalent of 150 million USD [1][2][4]. Summary by Sections 1. Transaction Overview - The company aims to engage in forward foreign exchange trading, including forward contracts and foreign exchange options, primarily for hedging purposes to reduce the impact of exchange rate and interest rate fluctuations on its operating performance [1][2]. - The maximum transaction amount for the forward foreign exchange trading is set at 150 million USD, with the highest contract value on any trading day not exceeding this amount [2]. 2. Funding Sources - The funding for the forward foreign exchange trading will primarily come from the company's own funds, without involving raised funds or bank credit [2]. 3. Trading Methods - The trading methods include, but are not limited to, foreign currency forward contracts and foreign exchange options, which allow the company to lock in exchange rates for future transactions [2][3]. 4. Trading Duration - The authorization period for these transactions is set for 12 months from the date of board approval, with the ability to roll over the authorized amount within this timeframe [4]. 5. Risk Analysis and Control Measures - The company adheres to principles of legality, prudence, safety, and effectiveness in its forward foreign exchange trading, avoiding speculative activities [4][5]. - A comprehensive internal control system has been established to manage risks associated with foreign exchange derivatives, including regular assessments and reporting to management [5]. 6. Impact on the Company - Engaging in forward foreign exchange trading is based on normal business operations and aims to enhance the company's ability to manage exchange rate risks without affecting normal cash flow or business operations [6]. 7. Compliance and Review - The proposed foreign exchange derivative trading has been reviewed and approved by the company's board and supervisory committee, complying with relevant laws and regulations [6].